I kliniske forsøg med AMMONAPS oplevede 56% af patienterne mindst én uønsket hændelse, og det blev antaget, at 78% af disse uønskede hændelser ikke var relateret til AMMONAPS.
In clinical trials with AMMONAPS, 56% of the patients experienced at least one adverse event and 78% of these adverse events were considered as not related to AMMONAPS.